State Street’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,594,542
| Closed | -$15.3M | – | 4349 |
|
|
2024
Q4 | $15.3M | Sell |
1,594,542
-116,023
| -7% | -$605K | ﹤0.01% | 2372 |
|
|
2024
Q3 | $4.89M | Buy |
1,710,565
+38,770
| +2% | +$120K | ﹤0.01% | 2982 |
|
|
2024
Q2 | $4.88M | Buy |
1,671,795
+220,814
| +15% | +$604K | ﹤0.01% | 2943 |
|
|
2024
Q1 | $4.63M | Buy |
1,450,981
+71,462
| +5% | +$238K | ﹤0.01% | 2961 |
|
|
2023
Q4 | $4.64M | Buy |
1,379,519
+152,303
| +12% | +$392K | ﹤0.01% | 2982 |
|
|
2023
Q3 | $2.92M | Buy |
1,227,216
+108,461
| +10% | +$227K | ﹤0.01% | 3164 |
|
|
2023
Q2 | $1.97M | Buy |
1,118,755
+884,288
| +377% | +$2.26M | ﹤0.01% | 3418 |
|
|
2023
Q1 | $722K | Buy |
234,467
+76,900
| +49% | +$461K | ﹤0.01% | 3629 |
|
|
2022
Q4 | $835K | Buy |
157,567
+64,600
| +69% | +$295K | ﹤0.01% | 3602 |
|
|
2022
Q3 | $328K | Hold |
92,967
| – | – | ﹤0.01% | 3930 |
|
|
2022
Q2 | $240K | Sell |
92,967
-438,606
| -83% | -$1.22M | ﹤0.01% | 4119 |
|
|
2022
Q1 | $2.38M | Sell |
531,573
-12,359
| -2% | -$55.7K | ﹤0.01% | 3496 |
|
|
2021
Q4 | $3.7M | Buy |
543,932
+22,419
| +4% | +$153K | ﹤0.01% | 3383 |
|
|
2021
Q3 | $3.8M | Buy |
521,513
+7,521
| +1% | +$64.5K | ﹤0.01% | 3373 |
|
|
2021
Q2 | $5.15M | Buy |
513,992
+62,314
| +14% | +$558K | ﹤0.01% | 3234 |
|
|
2021
Q1 | $4.31M | Buy |
451,678
+264,879
| +142% | +$2.6M | ﹤0.01% | 3108 |
|
|
2020
Q4 | $2.05M | Buy |
186,799
+55,151
| +42% | +$582K | ﹤0.01% | 3370 |
|
|
2020
Q3 | $1.17M | Buy |
+131,648
| New | +$1.5M | ﹤0.01% | 3398 |
|
Other funds holding PSTX
State Street's PSTX Position: Q1 2025 in Review
State Street sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 1,594,542 shares — an estimated $15.3M sold.
State Street first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $15.3M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- State Street reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- State Street sold 1,594,542 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $15.3M.
- State Street first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- State Street's Poseida Therapeutics, Inc. Common Stock position peaked at $15.3M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on State Street's 13F filing for Q1 2025, filed 15 May 2025.